Wikipedia

Ulf Kahlert

Ulf Dietrich Kahlert is a German cancer researcher and stem cell biologist. He is a professor at the Medical Faculty of the Otto-von-Guericke University Magdeburg (OvGU), where he leads the Department of Molecular and Experimental Surgery at the Clinic for General, Visceral, Vascular, and Transplant Surgery.[1] His extensive research work is documented in more than 95 international publications.[2][3][4][5]

Ulf Kahlert
Ulf Kahlert

Life

edit

Ulf Kahlert is the son of a physician, Ruth Kahlert, and an engineer, Jürgen Kahlert. He grew up in Dresden and studied biology at the University of Gießen, the University of Sussex in Brighton, UK, and the University of Freiburg, where he completed his diploma in 2008. He earned his PhD under the supervision of Wolfgang Driever in 2012 at the Faculty of Biology, focusing on cancer stem cells. As a fellow of the German Cancer Aid Foundation, he conducted postdoctoral research from 2013 to 2015 at Johns Hopkins Hospital in Baltimore, MD, USA, in the laboratory of Professor Charles G. Eberhart.[6]

Starting in October 2015, he led the Translational Neurotechnologies group at the Clinic for Neurosurgery at the University Hospital Düsseldorf. In November 2020, he habilitated at the Medical Faculty of the University of Düsseldorf on the topic of stem cell technology for precision oncology[7] and received Venia Legendi. In April 2021, he accepted a professorship for Molecular and Experimental Surgery at OvGU. Since 2023, he has been the head of Molecular Research at the AN-Institute for Quality Assurance in Operative Medicine at OvGU.[8] His research group participates in the STIMULATE campus, a public-private partnership focused on the development of modern medical technology. In 2024, he was appointed chairman of the Magdeburg local group of the German Association of University Professors and Lecturers[9] and chairman of the Commission for International Relations of the Faculty of Medicine at OvGU.[10]

Research fields

edit
  1. Cancer Stem Cell Research
    • Studies on the plasticity and heterogeneity of malignant solid tumors, particularly glioblastomas, pancreatic adenocarcinomas, and colorectal tumors.[11]
    • Development of new treatment approaches against therapy resistance and metastasis of tumors through personalized therapies focusing on the modulation of cell metabolism.[12][13][14][15]
    • Simulation of tumor development using healthy stem cells.[16]
    • Ensuring reproducible research results by developing alternative validation techniques.[17][16][18]
  2. Early Detection of Tumors
    • Using novel diagnostics for potential intra-operative or perioperative application.[19][20][21]
  3. Quality Improvement in Biomedical Research
    • Through enhanced reporting and quality management.[18]
  4. Animal-Free Alternative Methods
    • In the early stages of drug development.[22]

As part of the COST funding initiative of the European Union, Kahlert's research on the application of stem cells as a testing platform for assessing the specificities and efficiency of innovative nanomedicines against cancer cells was selected as a success story of all European research collaboration networks in 2023.[23]

References

edit
  1. ^ "Molekulare und Experimentelle Chirurgie (MEC)" (in German). Otto-von-Guericke-Universität Magdeburg. Retrieved 2024-09-19.
  2. ^ "Ulf Kahlert". Google Scholar. Retrieved 2024-09-23.
  3. ^ Yao, Qiuming; Kushwaha, Prem Prakash; Shi, Wenjie (2023-12-27). Machine Learning-Assisted Diagnosis and Treatment of Endocrine-Related Diseases. Frontiers Media SA. ISBN 978-2-8325-4235-4.
  4. ^ Steinhauser, Martin Oliver (2018-02-24). Multiscale Modeling and Simulation of Shock Wave-Induced Failure in Materials Science. Springer. ISBN 978-3-658-21134-9.
  5. ^ Liu, William J.; Sun, Peter; Wang, Qihui (2023-04-12). Crystal clear: Visualizing the immune recognition for the mechanism and intervention. Frontiers Media SA. ISBN 978-2-8325-2051-2.
  6. ^ "The Brain & Eye Tumor Lab: Alumni". Retrieved 2024-09-19.
  7. ^ "Abgeschlossene Habilitationsverfahren". Heinrich Heine Universität Düsseldorf (in German). Retrieved 2024-09-19.
  8. ^ "Experte für Stammzellforschung berufen" (in German). Otto-von-Guericke-Universität Magdeburg. 2021-10-01. Retrieved 2024-09-19.
  9. ^ "Der Landesverband Sachsen-Anhalt". Deutscher Hochschulverband. Retrieved 2024-09-19.
  10. ^ "Kommission für Internationale Beziehungen". Otto-von-Guericke-Universität Magdeburg. Retrieved 2024-09-23.
  11. ^ U. D. Kahlert, G. Nikkhah, J. Maciaczyk (2013-05-01), "Epithelial-to-mesenchymal(-like) transition as a relevant molecular event in malignant gliomas", Cancer Letters, vol. 331, no. 2, pp. 131–138, doi:10.1016/j.canlet.2012.12.010, ISSN 0304-3835, PMID 23268331, retrieved 2024-09-22{{citation}}: CS1 maint: multiple names: authors list (link)
  12. ^ "Magdeburger Forscher finden Biomarker zur Früherkennung von Bauchspeicheldrüsenkrebs" (in German). 2023-11-17. Retrieved 2024-09-22.
  13. ^ U. D. Kahlert, S. M. Mooney, M. Natsumeda, H.-J. Steiger, J. Maciaczyk (2017-01-01), "Targeting cancer stem-like cells in glioblastoma and colorectal cancer through metabolic pathways", International Journal of Cancer, vol. 140, no. 1, pp. 10–22, doi:10.1002/ijc.30259, ISSN 1097-0215, PMID 27389307, retrieved 2024-09-23{{citation}}: CS1 maint: multiple names: authors list (link)
  14. ^ Ulf D. Kahlert, Menglin Cheng, Katharina Koch, Luigi Marchionni, Xing Fan, Eric H. Raabe, Jarek Maciaczyk, Kristine Glunde, Charles G. Eberhart (2016-03-01), "Alterations in cellular metabolome after pharmacological inhibition of Notch in glioblastoma cells", International Journal of Cancer, vol. 138, no. 5, pp. 1246–1255, doi:10.1002/ijc.29873, ISSN 1097-0215, PMC 4772139, PMID 26422827{{citation}}: CS1 maint: multiple names: authors list (link)
  15. ^ "Wie könnte die Entwicklung von Krebsmedikamenten verbessert werden?" (in German). idw-online. 2022-07-05. Retrieved 2024-09-22.
  16. ^ a b "Validierungsprojekte: DisCoVer". BmBF: Validierungsförderung VIP+ (in German). Bundesministerium für Bildung und Forschung. Retrieved 2024-09-22.
  17. ^ Dilaware Khan, Ann-Christin Nickel, Sebastian Jeising, Constanze Uhlmann, Sajjad Muhammad, Daniel Hänggi, Igor Fischer, Ulf Dietrich Kahlert (2021-09-11), "Testing the Stability of Drug Resistance on Cryopreserved, Gene-Engineered Human Induced Pluripotent Stem Cells", Pharmaceuticals (Basel, Switzerland), vol. 14, no. 9, p. 919, doi:10.3390/ph14090919, ISSN 1424-8247, PMC 8466661, PMID 34577619{{citation}}: CS1 maint: multiple names: authors list (link)
  18. ^ a b "Krebsforschung: Der Weg zu mehr Qualität" (in German). DocCheck. Retrieved 2024-09-22.
  19. ^ Wenjie Shi, Thomas Wartmann, Sara Accuffi, Sara Al-Madhi, Aristotelis Perrakis, Christoph Kahlert, Alexander Link, Marino Venerito, Verena Keitel-Anselmino, Christiane Bruns, Roland S. Croner, Yue Zhao, Ulf D. Kahlert (2024), "Integrating a microRNA signature as a liquid biopsy-based tool for the early diagnosis and prediction of potential therapeutic targets in pancreatic cancer", British Journal of Cancer, vol. 130, no. 1, pp. 125–134, doi:10.1038/s41416-023-02488-4, ISSN 1532-1827, PMC 10781694, PMID 37950093{{citation}}: CS1 maint: multiple names: authors list (link)
  20. ^ Lennard M. Wurm, Björn Fischer, Volker Neuschmelting, David Reinecke, Igor Fischer, Roland S. Croner, Roland Goldbrunner, Michael C. Hacker, Jakub Dybaś, Ulf D. Kahlert (2023-11-20), "Rapid, label-free classification of glioblastoma differentiation status combining confocal Raman spectroscopy and machine learning", The Analyst, vol. 148, no. 23, pp. 6109–6119, Bibcode:2023Ana...148.6109W, doi:10.1039/d3an01303k, ISSN 1364-5528, PMID 37927114, retrieved 2024-09-23{{citation}}: CS1 maint: multiple names: authors list (link)
  21. ^ "CRISPR/Cas-Technologie ermöglicht schnelle und minimal-invasive Diagnostik". Heinrich Heine Universität Düsseldorf (in German). 2021-04-23. Retrieved 2024-09-23.
  22. ^ Constanze Uhlmann, Ann-Christin Nickel, Daniel Picard, Andrea Rossi, Guanzhang Li, Barbara Hildebrandt, Gabriele Brockerhoff, Farina Bendt, Ulrike Hübenthal, Michael Hewera, Hans-Jakob Steiger, Dagmar Wieczorek, Aristoteles Perrakis, Wei Zhang, Marc Remke, Katharina Koch, Julia Tigges, Roland S. Croner, Ellen Fritsche, Ulf D. Kahlert (2022), "Progenitor cells derived from gene-engineered human induced pluripotent stem cells as synthetic cancer cell alternatives for in vitro pharmacology", Biotechnology Journal, vol. 17, no. 6, pp. e2100693, doi:10.1002/biot.202100693, ISSN 1860-7314, PMID 35334498, retrieved 2024-09-23{{citation}}: CS1 maint: multiple names: authors list (link)
  23. ^ "COST: a career booster!". cost.eu. 2024-07-22. Retrieved 2024-09-22.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Ulf_Kahlert&oldid=1258101691"